Increased expression of PIM-2 and NF-κB genes in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is associated with complete remission rate and overall survival

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 67, Issue , 2013, Pages 553-559

  Kapelko Słowik, Katarzyna ^a   Urbaniak Kujda, Donata ^a   Wołowiec, Dariusz ^a   Jaźwiec, Bozena ^a   Dybko, Jarosław ^a   Jakubaszko, Jacek ^a   Słowik, Mirosław ^a   Kuliczkowski, Kazimierz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; NF B; PIM 2

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOPROTEIN; PIM2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; REFERENCE VALUE; REMISSION; SURVIVAL RATE; TUMOR CELL LINE; VERY ELDERLY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NF-KAPPA B; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; REFERENCE VALUES; REMISSION INDUCTION; SURVIVAL RATE; YOUNG ADULT;

EID: 84885108181     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1052449     Document Type: Article

References (32)

1. Adam M., Pogacic V., Bendit M., Chappuis R., Nawijn M. C., Duyster J., Fox C. J., Thompson C. B., Cools J., Schwaller J.: Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of FMS-like tyrosine kinase 3 and BCR/ABL. Cancer Res., 2006;66:3828-3835
2. Amson R., Sigaux F., Przedborski S., Flandrin G., Givol D., Telerman A.: The human proto-oncogene product p33pim is expressed during fetal haematopoiesis and in diverse leukaemias. Proc. Natl. Acad. Sci. USA, 1989;86:8857-8861
3. Asano J., Nakano A., Oda A., Amou H., Hiasa M., Takeuchi K., Miki H., Nakamura S., Harada T., Fujii S., Kagawa K., Endo I., Yata K., Sakai A., Ozaki S., Matsumoto T., Abe M.: The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia, 2011;25:1182-1188
4. Baytel D., Shalom S., Madgar I., Weissenberg R., Don J.: The human Pim-2 proto-oncogene and its testicular expression. Biochim. Biophys. Acta, 1998;1442:274-285
5. Beillard E., Pallisgaard N., van der Velden V H J., Bi W., Dee R., van der Schoot E., Delabesse E., Macintyre E., Gottardi E., Saglio G., Watzinger F., Lion T., van Dongen J. J., Hokland P., Gabert J.: Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia, 2003;17:2474-2486
6. Brault L., Gasser C., Bracher F., Huber K., Knapp S., Schwaller J.: PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica, 2010;95:1004-1015
7. Breuer M. L., Cuypers H. T., Berns A.: Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J., 1989;8:743-748
8. Chen L. S., Redkar S., Bearss D., Wierda W. G., Gandhi V.: Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood, 2009;114:4150-4157
9. Cheson B. D., Bennett J. M., Kopecky K. J., Büchner T., Willman C. L., Estey E. H., Schiffer C. A., Doehner H., Tallman M. S., Lister T. A., Lo-Coco F., Willemze R., Biondi A., Hiddemann W., Larson R. A., Löwenberg B., Sanz M. A., Head D. R., Ohno R., Bloomfield C. D., International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J. Clin. Oncol., 2003;21:4642-4649
10. Cohen A. M., Grinblat B., Bessler H., Kristt D., Kremer A., Schwartz A., Halperin M., Shalom S., Merkel D., Don J.: Increased expression of the hPim-2 gene in human chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Leuk. Lymphoma, 2004;45:951-955
11. Dai H., Li R., Wheeler T., Diaz de Vivar A., Frolov A., Tahir S., Agoulnik I., Thompson T., Rowley D., Ayala G.: Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate, 2005;65:276-286
12. Dai J. M., Zhang S. Q., Zhang W., Lin R. X., Ji Z. Z., Wang S. Q.: Antisense oligodeoxynucleotides targeting the serine/threonine kinase Pim-2 inhibited proliferation of DU-145 cells. Acta Pharmacol. Sin., 2005;26:364-368
13. Fox C. J., Hammerman P. S., Cinalli R. M., Master S. R., Chodosh L. A., Thompson C. B.: The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Gene Dev., 2003;17:1841-1854
14. Giebel S., Holowiecki J., Krawczyk-Kulis M., Jagoda K., Stella-Holowiecka B., Sadus-Wojciechowska M., Hellmann A., Dmoszynska A., Paluszewska M., Robak T., Konopka L., Seferynska I., Skotnicki A. B., Kyrcz-Krzemien S.: Impact of granulocyte colony stimulating factor administered during induction and consolidation of adults with acute lymphoblastic leukemia on survival: long-term follow-up of the Polish adult leukemia group 4-96 study. Leuk. Lymphoma, 2009;50:1050-1053
15. Gong J., Wang J., Ren K., Liu C., Li B., Shi Y.: Serine/threonine kinase Pim-2 promotes liver tumorigenesis induction through mediating survival and preventing apoptosis of liver cell. J. Surg. Res., 2009;153:17-22
16. Hammerman P. S., Fox C. J., Brinbaum M. J., Thompson C. B.: Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood, 2005;105:4477-4483
17. Hammerman P. S., Fox C. J., Cinalli R. M., Xu A., Wagner J. D., Lindsten T., Thompson C. B.: Lymphocyte transformation by Pim-2 is dependent on nuclear factor-κB activation. Cancer Res., 2004;64:8341-8348
18. Hołowiecki J., Grosicki S., Robak T., Kyrcz-Krzemien S., Giebel S., Hellmann A., Skotnicki A., Jedrzejczak W. W., Konopka L., Kuliczkowski K., Zdziarska B., Dmoszynska A., Marianska B., Pluta A., Zawilska K., Komarnicki M., Kloczko J., Sulek K., Haus O., Stella-Holowiecka B., Baran W., Jakubas B., Paluszewska M., Wierzbowska A., Kielbinski M., Jagoda K., Polish Adult Leukemia Group (PALG): Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia, 2004;18:989-997
19. Kapelko-Słowik K., Urbaniak-Kujda D., Wołowiec D., Dybko J., Słowik M., Potoczek S., Kuliczkowski K.: Human Pim-2 expression in acute myeloid and acute lymphoblastic leukemia patients and complete remission. Adv. Clin. Exp. Med., 2010;19, 99-104
20. Karin M., Lin A.: NF-κB at the crossroads of life and death. Nat. Immunol., 2002;3:221-227
21. Li Q., Verma I. M.: NF-κB regulation in the immune system. Nat. Rev. Immunol., 2002;2:725-734
22. Lin A., Karin M.: NF-κB in cancer: a marked targed. Semin. Cancer Biol., 2003;13:107-114
23. Macdonald A., Campbell D. G., Toth R., McLauchlan H., Hastie C. J., Arthur J. S.: Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol., 2006;7:1-14
24. Mikkers H., Allen J., Knipscheer P., Romeijn L., Hart A., Vink E., Berns A.: High-throughput retroviral tagging to indentify components of specific signaling pathways in cancer. Nat. Genet., 2002;32:153-159
25. Mizuki M., Schwable J., Steur C., Choudhary C., Agrawal S., Sargin B., Steffen B., Matsumura I., Kanakura Y., Böhmer F. D., Müller-Tidow C., Berdel W. E., Serve H.: Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood, 2003;101:3164-3173
26. Reeves R., Spies G. A., Kiefer M., Barr P. J., Power M.: Primary structure of the putative human oncogene, pim-1. Gene, 1990;90:303-307
27. Ren K., Duan W., Shi Y., Li B., Liu Z., Gong J.: Ectopic over-expression of oncogene Pim-2 induce malignant transformation of nontumorous human liver cell line L02. J. Korean Med. Sci., 2010;25:1017-1023
28. Ren K., Zhang W., Shi Y., Gong J.: Pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-κB pathway. Pathol. Oncol. Res., 2010;16:229-237
29. Tamburini J., Green A. S., Bardet V., Chapuis N., Park S., Willems L., Uzunov M., Ifrah N., Dreyfus F., Lacombe C., Mayeux P., Bouscary D.: Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood, 2009;114:1618-1627
30. White E.: The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev., 2003;17:1813-1816
31. Yan B., Zemskova M., Holder S., Chin V., Kraft A., Koskinen P. J., Lilly M.: The PIM-2 kinase phosphorylates Bad on serine 112 and reverses Bad-induced cell death. J. Biol. Chem., 2003;278:45358-45367
32. Zhang S. Q., Du Q. Y., Ying Y., Ji Z. Z., Wang S. Q.: Polymerase synthesis and potential interference of a small-interfering RNA targeting hPim-2. World J. Gastroenterol., 2004;10:2657-2660